Eli Lilly (LLY)
767.07
+16.29 (2.17%)
NYSE · Last Trade: Jun 4th, 4:09 PM EDT
Detailed Quote
Previous Close | 750.78 |
---|---|
Open | 756.39 |
Bid | 766.87 |
Ask | 767.27 |
Day's Range | 756.00 - 772.62 |
52 Week Range | 677.09 - 972.53 |
Volume | 2,353,857 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.000 (0.78%) |
1 Month Average Volume | 5,091,992 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
Via Benzinga · June 4, 2025

Dive deep into two popular dividend ETFs to determine which is right for your portfolio.
Via The Motley Fool · June 4, 2025

Via The Motley Fool · June 4, 2025

The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.
Via Investor's Business Daily · June 3, 2025

Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly.
Via Benzinga · June 2, 2025

A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.
Via Benzinga · June 2, 2025

Via PR Leap · June 2, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · May 30, 2025

There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Via Investor's Business Daily · May 30, 2025

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Via Investor's Business Daily · May 30, 2025

Via The Motley Fool · May 30, 2025

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Via Investor's Business Daily · May 29, 2025

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.
Via MarketBeat · May 29, 2025

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.
Via The Motley Fool · May 28, 2025
Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.
Via Benzinga · May 27, 2025